Literature DB >> 2844622

Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis.

R S Blumberg1, S Chopra, R Ibrahim, J Crawford, F A Farraye, J B Zeldis, M D Berman.   

Abstract

Previous reports have emphasized the association of primary hepatocellular carcinoma in patients with idiopathic hemochromatosis with cirrhosis. In contrast, patients with idiopathic hemochromatosis without cirrhosis have no increased risk of hepatocellular carcinoma. Phlebotomy therapy, by preventing the accumulation of parenchymal iron and subsequent cirrhosis, is believed to prevent hepatocellular carcinoma in the precirrhotic stage of the disease. We report the case of a 67-yr-old man with a 32-yr history of idiopathic hemochromatosis complicated by cirrhosis, who had reversal of cirrhosis with phlebotomy therapy, yet developed hepatocellular carcinoma. There was no serologic or tissue evidence of hepatitis B infection.

Entities:  

Mesh:

Year:  1988        PMID: 2844622     DOI: 10.1016/0016-5085(88)90379-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

Review 1.  Hepatocellular carcinoma in non-cirrhotic liver without evidence of iron overload in a patient with primary hemochromatosis. Review.

Authors:  Parminder Singh; Harneet Kaur; Robert G Lerner; Roshan Patel; Shamudheen M Rafiyath; Gurpreet Singh Lamba
Journal:  J Gastrointest Cancer       Date:  2012-03

Review 2.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

3.  Hepatocellular carcinoma in idiopathic haemochromatosis.

Authors:  F Sheehan; C E Connolly; C F McCarthy
Journal:  Gut       Date:  1989-06       Impact factor: 23.059

Review 4.  Aetiology and pathophysiology of chronic liver disorders.

Authors:  J Schölmerich; A Holstege
Journal:  Drugs       Date:  1990       Impact factor: 9.546

5.  The Treatment of Hepatic Fibrosis: Reversal of the Underlying Disease Process.

Authors:  Luis Servin-Abad; Eugene R Schiff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-11

6.  Epidemiology of primary and secondary liver cancers.

Authors:  Ashwin Ananthakrishnan; Veena Gogineni; Kia Saeian
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

Review 7.  [Quality and quantity in hepatopathology. Diagnostic and clinically relevant grading for non-tumourous liver diseases].

Authors:  T Longerich; C Flechtenmacher; P Schirmacher
Journal:  Pathologe       Date:  2008-02       Impact factor: 1.011

Review 8.  Hepatocellular carcinoma and African iron overload.

Authors:  I T Gangaidzo; V R Gordeuk
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

Review 9.  MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled.

Authors:  Catherine M Greene; Robert B Varley; Matthew W Lawless
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

Review 10.  Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies.

Authors:  Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-07       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.